bluebird bio (NASDAQ:BLUE) had its price target upped by SunTrust Banks to $223.00 in a research report issued on Tuesday, The Fly reports. The brokerage currently has a “buy” rating on the biotechnology company’s stock. SunTrust Banks’ price target would indicate a potential upside of 10.51% from the stock’s current price.

A number of other equities analysts also recently commented on the stock. Wells Fargo & Company reaffirmed an “outperform” rating and set a $242.00 price objective (up from $190.00) on shares of bluebird bio in a report on Tuesday. BMO Capital Markets set a $215.00 price objective on shares of bluebird bio and gave the stock a “buy” rating in a report on Monday. Jefferies Group raised shares of bluebird bio from a “hold” rating to a “buy” rating and raised their price objective for the stock from $130.00 to $211.00 in a report on Monday. Cantor Fitzgerald set a $113.00 price objective on shares of bluebird bio and gave the stock an “underweight” rating in a report on Monday. Finally, Canaccord Genuity began coverage on shares of bluebird bio in a report on Tuesday, December 5th. They set a “buy” rating and a $202.00 price objective for the company. Two analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $155.10.

Shares of bluebird bio (NASDAQ BLUE) opened at $201.80 on Tuesday. bluebird bio has a 12-month low of $60.95 and a 12-month high of $222.03.

bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.68) by ($0.05). The company had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. bluebird bio had a negative return on equity of 28.79% and a negative net margin of 883.18%. The business’s revenue for the quarter was up 397.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($2.07) earnings per share. equities research analysts predict that bluebird bio will post -6.68 earnings per share for the current fiscal year.

In related news, Director John Maraganore sold 18,868 shares of bluebird bio stock in a transaction dated Thursday, September 14th. The shares were sold at an average price of $131.21, for a total transaction of $2,475,670.28. Following the completion of the transaction, the director now directly owns 24,711 shares of the company’s stock, valued at approximately $3,242,330.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Davidson sold 4,000 shares of bluebird bio stock in a transaction dated Monday, October 2nd. The shares were sold at an average price of $131.31, for a total transaction of $525,240.00. The disclosure for this sale can be found here. Insiders have sold a total of 99,550 shares of company stock valued at $14,413,376 over the last three months. 3.90% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Candriam Luxembourg S.C.A. raised its stake in shares of bluebird bio by 31.7% in the fourth quarter. Candriam Luxembourg S.C.A. now owns 58,200 shares of the biotechnology company’s stock worth $3,738,000 after acquiring an additional 14,000 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in shares of bluebird bio by 78.0% during the 3rd quarter. Tocqueville Asset Management L.P. now owns 55,690 shares of the biotechnology company’s stock worth $7,649,000 after buying an additional 24,400 shares during the period. Baillie Gifford & Co. grew its holdings in bluebird bio by 2.1% during the fourth quarter. Baillie Gifford & Co. now owns 4,883,321 shares of the biotechnology company’s stock valued at $313,607,000 after purchasing an additional 99,617 shares during the period. Russell Investments Group Ltd. acquired a new position in bluebird bio during the fourth quarter valued at approximately $1,477,000. Finally, GAM Holding AG acquired a new position in bluebird bio during the fourth quarter valued at approximately $2,717,000.

ILLEGAL ACTIVITY WARNING: “SunTrust Banks Boosts bluebird bio (BLUE) Price Target to $223.00” was first posted by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/12/suntrust-banks-boosts-bluebird-bio-blue-price-target-to-223-00.html.

About bluebird bio

bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).

The Fly

Analyst Recommendations for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.